HC Wainwright Rates Faeth Therapeutics (FTH) buy
HC Wainwright maintains its buy rating on Faeth Therapeutics with a $60 price target, a 144.50% upside from the current price.
Reviewed by automated data checks against the source data. How we make and check alerts
HC Wainwright rated Faeth Therapeutics, Inc. ($FTH) "buy" with a $60 price target on June 22, 2026.
Since the rating, $FTH is up 0.1% after 1 week, up 23.6% after 1 month and down 18.9% to date (from the $23.19 close on Jun 22, 2026).
FTH
Faeth Therapeutics, Inc.
Key Points
- HC Wainwright reiterated its buy rating for Faeth Therapeutics, Inc. (FTH) with a $60 price target on June 22, 2026.
- HC Wainwright's $60 price target implies 144.50% upside from Faeth Therapeutics, Inc.'s ($FTH) current $24.54 share price.
- Faeth Therapeutics, Inc. is a biotechnology company focused on cancer therapeutics, trading at $17.82 on Tuesday.
- The company has a market cap of $597.8 million, with a strong buy consensus and a target mean price of $52.5 from four analysts.
Get $FTH trade alerts by text
We text you when insiders, Congress or big funds trade $FTH. Free.
Not investment advice. TradeTexts is not a registered investment adviser, and this automated Faeth Therapeutics, Inc. alert may contain errors. Disclosures
HC Wainwright reaffirmed its buy rating for Faeth Therapeutics, Inc. (NasdaqCM: FTH) on June 22, 2026, maintaining a price target of $60. This reiteration comes as the company continues its focus on developing cancer therapeutics.
HC Wainwright & Co. vs. the S&P 500
Hypothetical returns from HC Wainwright & Co.'s disclosed trades, not real profit or advice. How we model this.
Faeth Therapeutics, Inc. Stock Down 28.9%
Shares of NasdaqCM:FTH traded near $17.82 on Tuesday. Faeth Therapeutics, Inc. has a market cap of approximately $597.8 million and a beta of -0.231, indicating lower volatility compared to the market. The stock has seen a 52-week low of $6.33 and a high of $36.76. Its 50-day moving average is $22.11, while the 200-day moving average stands at $16.41. The company boasts a strong current ratio of 14.39 and a quick ratio of 14.29.
$FTH price target
Faeth Therapeutics, Inc. daily closes and this analyst's $60 target. Not advice.
Analysts Set New Price Targets
On June 22, 2026, HC Wainwright & Co. reiterated its buy rating for Faeth Therapeutics with a price target of $60. The consensus among analysts is a strong buy, with a target mean price of $52.5, derived from four analyst opinions.
About Faeth Therapeutics
Faeth Therapeutics, Inc. is a clinical-stage biotechnology company based in Rockville, Maryland. It specializes in discovering and developing therapeutics for cancer patients. The company's key products include PIKTOR, an investigational inhibitor for endometrial and breast cancer, and Solnerstotug, a monoclonal antibody in clinical trials targeting solid tumors. Faeth's pipeline also includes early-stage antibodies SNS-102 and SNS-103, and SNS-201, a bispecific antibody targeting CD28. Originally known as Sensei Biotherapeutics, Inc., the company rebranded to Faeth Therapeutics in June 2026.
Bottom Line
HC Wainwright's reaffirmation of a buy rating for Faeth Therapeutics underscores confidence in the company's prospects. Investors closely follow such analyst ratings to gauge market sentiment and potential future performance. As a reminder, these ratings are based on past data and do not necessarily reflect current positions or future outcomes.
Related Filing Alerts
Source: HC Wainwright's rating change on $FTH (Jun 22, 2026). Written by software, not financial advice. How we make alerts